STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] EKSO BIONICS HOLDINGS, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ekso Bionics Holdings (EKSO) reported an insider equity grant on Form 4. On November 5, 2025, the Chief Operating Officer received 15,000 restricted stock units (RSUs) at a stated price of $0. The filing states the award was fully vested at grant under the company’s Amended and Restated 2014 Equity Incentive Plan.

Following the transaction, the reporting person beneficially owns 36,934 shares directly and 3,141 shares indirectly via a 401(k). Share amounts reflect the 1-for-15 reverse stock split effected on June 2, 2025.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jones Jason C

(Last) (First) (Middle)
101 GLACIER POINT
SUITE A

(Street)
SAN RAFAEL CA 94901

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/05/2025 A 15,000(1)(2) A $0 36,934(3) D
Common Stock 3,141(3) I By 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting.
2. The RSU grant was approved by the Board of Directors in a meeting held on November 5, 2025, under the Company's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). Each RSU Award was fully vested at grant.
3. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
/s/ Jerome Wong 11/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EKSO disclose in this Form 4?

A grant of 15,000 RSUs to the Chief Operating Officer on November 5, 2025, fully vested at grant.

How many shares does the reporting person own after the grant (EKSO)?

Beneficial ownership is 36,934 shares directly and 3,141 shares indirectly via a 401(k).

What is the vesting status of the RSU award for EKSO?

The filing states the RSU award was fully vested at grant.

Under which plan were the EKSO RSUs granted?

Under the company’s Amended and Restated 2014 Equity Incentive Plan.

Does the EKSO Form 4 reflect a stock split adjustment?

Yes. Amounts reflect the 1-for-15 reverse stock split effective June 2, 2025.

What security type was granted in the EKSO filing?

Restricted stock units (RSUs), each representing the economic equivalent of one common share.
Ekso Bionics

NASDAQ:EKSO

EKSO Rankings

EKSO Latest News

EKSO Latest SEC Filings

EKSO Stock Data

12.72M
3.24M
4.95%
2.75%
5.14%
Medical Instruments & Supplies
General Industrial Machinery & Equipment, Nec
Link
United States
SAN RAFAEL